AbbVie (NYSE: ABBV) recently received a number of ratings updates from brokerages and research firms:
- 11/18/2026 – AbbVie was given a new $349.00 price target by Piper Sandler. They now have an “overweight” rating on the stock.
- 11/16/2026 – AbbVie had its price target raised by Barclays from $325.00 to $335.00. They now have an “overweight” rating on the stock.
- 11/4/2026 – AbbVie was given a new $315.00 price target by BMO Capital Markets.
- 11/2/2026 – AbbVie had its “market perform” rating reaffirmed by Sanford C. Bernstein. They now have a $275.00 price target on the stock.
- 11/2/2026 – AbbVie had its price target raised by Guggenheim from $288.00 to $322.00. They now have a “buy” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by Wells Fargo & Company from $300.00 to $340.00. They now have an “overweight” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by UBS Group from $275.00 to $295.00. They now have a “neutral” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by Leerink Partners from $309.00 to $342.00. They now have an “outperform” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by Morgan Stanley from $310.00 to $346.00. They now have an “overweight” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by Royal Bank Of Canada from $280.00 to $330.00. They now have an “outperform” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by Cantor Fitzgerald from $290.00 to $325.00. They now have an “overweight” rating on the stock.
- 11/2/2026 – AbbVie had its price target raised by Canaccord Genuity Group from $290.00 to $338.00. They now have a “buy” rating on the stock.
- 10/23/2026 – AbbVie had its price target raised by The Goldman Sachs Group from $258.00 to $294.00. They now have a “neutral” rating on the stock.
- 10/21/2026 – AbbVie had its price target raised by Barclays from $300.00 to $325.00. They now have an “overweight” rating on the stock.
- 10/13/2026 – AbbVie had its “outperform” rating reaffirmed by Royal Bank Of Canada. They now have a $280.00 price target on the stock.
- 10/9/2026 – AbbVie had its “buy” rating reaffirmed by Guggenheim. They now have a $288.00 price target on the stock.
- 10/8/2026 – AbbVie was upgraded by Weiss Ratings from “buy (b-)” to “buy (b)”.
- 10/8/2026 – AbbVie had its price target raised by JPMorgan Chase & Co. from $285.00 to $300.00. They now have an “overweight” rating on the stock.
- 10/8/2026 – AbbVie had its price target raised by Cantor Fitzgerald from $285.00 to $290.00. They now have an “overweight” rating on the stock.
- 10/7/2026 – AbbVie had its price target raised by Morgan Stanley from $296.00 to $310.00. They now have an “overweight” rating on the stock.
- 10/6/2026 – AbbVie had its price target raised by Scotiabank from $280.00 to $320.00. They now have an “outperform” rating on the stock.
- 10/6/2026 – AbbVie had its price target raised by UBS Group from $260.00 to $275.00. They now have a “neutral” rating on the stock.
- 10/6/2026 – AbbVie had its price target raised by Scotiabank from $280.00 to $320.00. They now have a “sector outperform” rating on the stock.
AbbVie Price Performance
NYSE ABBV opened at $283.36 on Friday. The company has a 50 day simple moving average of $278.40 and a 200-day simple moving average of $242.25. The firm has a market capitalization of $500.87 billion, a price-to-earnings ratio of 48.77, a price-to-earnings-growth ratio of 1.30 and a beta of 0.20. AbbVie Inc. has a 52-week low of $190.75 and a 52-week high of $302.93.
AbbVie (NYSE:ABBV – Get Free Report) last posted its earnings results on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The firm had revenue of $17.40 billion during the quarter, compared to analysts’ expectations of $17.32 billion. During the same period in the previous year, the company earned $1.86 earnings per share. The company’s revenue was up 10.3% compared to the same quarter last year. On average, analysts predict that AbbVie Inc. will post 13.98 EPS for the current year.
AbbVie Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 16th. Stockholders of record on Friday, January 15th will be given a dividend of $1.82 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.73. This represents a $7.28 dividend on an annualized basis and a dividend yield of 2.6%. The ex-dividend date is Friday, January 15th. AbbVie’s dividend payout ratio (DPR) is presently 125.30%.
Insider Activity
In other news, EVP Jeffrey Stewart sold 40,619 shares of the stock in a transaction on Monday, November 9th. The shares were sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president owned 83,171 shares in the company, valued at approximately $24,419,005.60. This represents a 32.81% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 0.06% of the company’s stock.
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
- Five stocks we like better than AbbVie
- Grand Theft Auto VI Arrives: Why Take-Two Is a Waiting Game
- Greg Abel Makes His Next Moves: Inside Berkshire’s Q3 Portfolio
- Walmart Earnings Change the Narrative as Digital Growth Lifts Outlook
- Whatever Happens to Copper Next, These 3 Investments Offer Different Ways to Play It
Receive News & Ratings for AbbVie Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie Inc and related companies with MarketBeat.com's FREE daily email newsletter.
